For the first time, the country produces positronic radiopharmaceuticals; labeled with a

radionuclide obtained in a cyclotron. Its introduction into the National Health System allows a qualitative leap in applying more precise oncological treatment techniques.

Its commercial name is F-Glutep, and the molecule has been recorded at the Cuban Industrial Property Office, Granma newspaper reports.

The Nuclear Energy and Advanced Technologies Agency awarded the work “Results of the introduction of the 18F-FDG molecule in the National Health System” with one of its 2022 prizes.

jrr/iff/mem/joe